Re-treatment enhances vision

Article

Dr Dell uses wavefront-guided LASIK for enhancements of wavefront-optimized laser vision correction in patients who are unhappy with their quality of vision. By treating these patients' higher-order aberrations with a custom re-treatment, their symptoms resolve and they are much more satisfied.

Some patients who have had previous wavefront-optimized laser vision correction present with quality-of-vision complaints, such as halo and glare, despite having 20/20 visual acuity. After enhancement with custom wavefront-guided laser vision correction to address their higher-order aberrations, patients often report that symptoms resolve and they are much more satisfied with their overall quality of vision.

Laser vision correction options

Laser vision correction has evolved into two different schools of thought. One is based upon a customized wavefront-guided treatment [iLASIK Suite, Abbott Medical Optics (AMO)] in which the patient's wavefront map is used to create a customized treatment pattern that conforms to the degree of spherical aberration, coma and other higher-order terms that the particular patient has. The iLASIK Suite includes the STAR S4 Iris Registration System with the WaveScan System and iFS femtosecond laser. The advantage of using this type of system is that it is literally customized to the individual characteristics of each patient's eye. However, it can be more labour intensive. A good wavefront map needs to be obtained on all patients and that requires an added step in the process of working up a patient.

Wavefront-optimized treatment (Allegretto Wave Eye-Q Excimer Laser, Alcon Laboratories) is the other form of modern laser vision correction in the US today. This type of laser vision correction has a more simple approach. Wavefront measurements are not required and this procedure can be performed by only using the refractive error of the patient. However, assumptions are made regarding the degree of spherical aberrations present in any given eye. As a result, the spherical aberration correction is good enough to produce excellent results for a portion of patients undergoing treatment with an optimized platform, but in some patients the spherical aberration correction is insufficient and in other patients the pre-set spherical aberration correction actually makes the situation worse. An example of this would be a case in which a patient starts out with negative spherical aberration and then an additional negative spherical aberration is added using the ablation.

Overall, both forms of laser vision correction provide very good results for most patients, but customizing the ablation to the individual patient has some important advantages. Some have argued that correcting higher-order aberrations on the cornea might create issues as a patient experiences future lens changes with age. Careful study of the wavefront treatment algorithm in the AMO VISX laser shows that the majority of the wavefront-guided customization is applied to spherical aberration and asymmetrical astigmatism (coma) and correcting those two factors is very likely to serve a patient well throughout the course of a lifetime.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.